Lonza is acquiring a 58,000 square foot clinical-stage mammalian manufacturing site in the U.S. from Shire. The site is located in Hayward, CA and has been operating as a multiproduct cGMP facility since 1990 with a successful regulatory track record. Assets include 1,000L and 2,000L single-use bioreactors and associated downstream capabilities. Currently the site employs more than 100 personnel, all of whom will have the opportunity to continue in their role with Lonza. Financial details of the...